Breaking News Instant updates and real-time market news.

AET

Aetna

$114.46

0.99 (0.87%)

, MRK

Merck

$63.90

1.13 (1.80%)

08:47
10/11/16
10/11
08:47
10/11/16
08:47

Aetna, Merck announce value-based contract for Januvia and Janumet

Aetna (AET) announced that it has entered into a value-based agreement with Merck (MRK) for the type 2 diabetes medications Januvia and Janumet. Under this agreement, Merck's rebates on Januvia and Janumet will be based in part on those products' contributions to helping Aetna's commercial member population with type 2 diabetes achieve or maintain treatment objectives. In a separate initiative, Merck is also collaborating with Aetna on AetnaCare, a new health approach which uses predictive analytics to identify target populations and proactively curate various health and wellness services that are available to each member. "Working with a patient's physicians and other caregivers, the program is designed to support treatment adherence, ensure that critical social support needs are met, and reinforce healthy lifestyle behaviors. The AetnaCare program will initially target patients with diabetes and hypertension in Mid-Atlantic markets," the companies stated. Merck has used its insights and experience to develop educational resources and tools to help address patient engagement, patient behavior and treatment adherence. Aetna will incorporate some of these resources from Merck's inventory into AetnaCare to support more effective patient self-management, the companies explained.

AET

Aetna

$114.46

0.99 (0.87%)

MRK

Merck

$63.90

1.13 (1.80%)

  • 25

    Oct

  • 06

    Nov

  • 10

    Nov

AET Aetna
$114.46

0.99 (0.87%)

08/22/16
LEER
08/22/16
NO CHANGE
LEER
Leerink less positive that Anthem challenge to DOJ lawsuit will be successful
Following a conference call with an anti-trust specialist, Leerink analyst Ana Gupte is less positive that the Anthem (ANTM) challenge to the lawsuit by the DOJ will be successful. The analyst says that the specialist views the obstacles to a defense by Anthem-Cigna (CI) to the anti-trust concerns as too numerous to result in a successful close. Further, the analyst believes that any favorable decision, however unlikely, on the merger close, will likely be appealed by the DOJ. Nonetheless, the lower likelihood of this defense being successful may improve the odds of a successful Aetna (AET)-Humana (HUM) defense, the analyst notes.
08/25/16
COWN
08/25/16
NO CHANGE
COWN
Managed Care mergers unlikely to close, says Cowen
Cowen analyst Christine Arnold believes the current managed care mergers including Aetna (AET) and Humana (HUM) and Anthem (ANTM) and Cigna (CI) are unlikely to close. The analyst said the government's ability to appeal could extend the litigation process beyond the termination dates stipulated in the merger agreements. Arnold believes the Aetna/Humana merger has a better chance of closing relative to the Anthem/Cigna deal, but believes neither are likely to close.
09/22/16
EVER
09/22/16
INITIATION
Target $128
EVER
Buy
Aetna initiated with a Buy at Evercore ISI
Evercore ISI analyst Michael Newshel initiated Aetna with a Buy and a $128 price target.
09/29/16
PACS
09/29/16
DOWNGRADE
PACS
Underweight
Pacific Crest cuts Fitbit to sell, sees share downside to $11
Pacific Crest analyst Brad Erickson downgraded Fitbit (FIT) to Underweight from Sector Weight after his channel checks indicated that Charge 2, the company's flagship holiday product, is off to a slow start. Underweight is Pacific Crest's equivalent of a sell rating. Charge 2 inventory is accumulating in the channel and sell-through is below initial Blaze/Alta levels, Erickson tells investors in a research note. The analyst continues to believe that a large portion of Fitbit owners stop using the device within months. Further, he views the corporate wellness deal between Aetna (AET) and Apple (AAPL) as a "substantial negative" for Fitbit. Erickson sees downside to $11 for shares of Fitbit. The stock closed yesterday up 17c to $16.70.
MRK Merck
$63.90

1.13 (1.80%)

10/10/16
LEER
10/10/16
NO CHANGE
LEER
Outperform
Leerink sees Bristol-Myers sliding after Merck's 'spectacular' Keytruda data
Leerink analyst Seamus Fernandez said Bristol-Myers' (BMY) Checkmate-026 data presented at the European Society of Medical Oncology meeting was disappointing, noting there was no signal of benefit on progression-free survival or overall survival and only "modest differentiation" on response rate in the 88 patients with PDL1 biomarker positivity greater than or equal to 50%. Meanwhile, Merck (MRK) presented "spectacular" data for Keytruda monotherapy at the meeting, said Fernandez, who expects Bristol shares to be down "significantly" today in light of the meeting presentations. The analyst, who still thinks Bristol has a significant opportunity to compete with Merck's Keytruda in the PDL1 high portion of the market, keeps an Outperform rating on Bristol shares, which are down nearly 6% in pre-market trading.
10/10/16
BMOC
10/10/16
NO CHANGE
BMOC
Merck should strengthen leadership in first line NSCLC, says BMO Capital
BMO Capital analyst Alex Arfaei says that upcoming data should strengthen Merck's (MRK) lead in 1L NSCLC. The analyst adds that the data could support off-label use of Merck's Keytruda in additional 1L NSCLC patients, and he says that the data "should be negative" for Bristol-Myers' (BMY) Opdivo drug. Arfaei keeps an Outperform rating on Merck and a Market Perform rating on Bristol-Myers.
10/10/16
LEER
10/10/16
NO CHANGE
LEER
Market Perform
Merck 'steals the show' at ESMO with Keytruda data, says Leerink
Leerink analyst Seamus Fernandez said Merck (MRK) stole the show at ESMO with its Keytruda data and he continues to think the company will dominate first line lung cancer treatment for years to come in patients with 50%+ PDL1 expression. Additionally, he expects Merck to gain additional traction in the overall market, noting that confirmation that Keytruda is benefiting patients when combined with Alimta/carboplatin with Alimta maintenance raises the possibility Merck could compete broadly in the overall non-squamous patient population. However, Fernandez keeps a Market Perform rating on Merck, as he thinks its current valuation largely reflects improved growth prospects through 2020.
10/10/16
JMPS
10/10/16
NO CHANGE
JMPS
Incyte treatment looking 'promising,' says JMP Securities
After reviewing recent data, JMP Securities analyst Liisa Bayko says that the combination of Incyte's (INCY) Epacadostat plus Merck's (MRK) Keytruda is "emerging as a promising treatment, potentially even best in class." The analyst says that the progression free survival rate of the combination in melanoma patients "is emerging to be quite competitive," while the efficacy rate in other solid tumors "seemed encouraging." The analyst raised her price target on Incyte to $110 from $100 and keeps an Outperform rating on the stock.

TODAY'S FREE FLY STORIES

CMG

Chipotle

$309.49

6.08 (2.00%)

12:41
09/20/17
09/20
12:41
09/20/17
12:41
Hot Stocks
Ackman calls Chipotle shares 'extremely cheap' »

Bill Ackman of Pershing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FSLR

First Solar

$48.86

0.32 (0.66%)

12:36
09/20/17
09/20
12:36
09/20/17
12:36
Hot Stocks
First Solar off lows after Deutsche's analysis of Friday's ITC ruling »

The shares remain down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FSLR

First Solar

$48.86

0.32 (0.66%)

12:35
09/20/17
09/20
12:35
09/20/17
12:35
Recommendations
First Solar analyst commentary  »

First Solar shares can…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:35
09/20/17
09/20
12:35
09/20/17
12:35
General news
FOMC forecast revisions »

FOMC forecast revisions…

AA

Alcoa

$47.30

1.1 (2.38%)

12:30
09/20/17
09/20
12:30
09/20/17
12:30
Options
All time high for Alcoa shares draws December premium buyers »

All time high for Alcoa…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GM

General Motors

$38.99

0.29 (0.75%)

12:25
09/20/17
09/20
12:25
09/20/17
12:25
Periodicals
GM and striking workers union Unifor in informal talks, Automotive News says »

General Motors and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADP

ADP

$107.48

0.93 (0.87%)

12:21
09/20/17
09/20
12:21
09/20/17
12:21
Hot Stocks
Ackman says ADP CEO's stake lot more levered than Pershing's »

Pershing Square's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADP

ADP

$107.48

0.93 (0.87%)

12:20
09/20/17
09/20
12:20
09/20/17
12:20
Hot Stocks
Ackman says ADP stock options owned are 'very deep in the money' »

Pershing Square's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSIQ

Canadian Solar

$16.71

-0.09 (-0.54%)

12:20
09/20/17
09/20
12:20
09/20/17
12:20
Options
Aggressive put buying in Canadian Solar »

Aggressive put buying in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADP

ADP

$107.48

0.93 (0.87%)

12:18
09/20/17
09/20
12:18
09/20/17
12:18
Hot Stocks
ADP board has no shareholder orientation, Ackman says »

Pershing Square's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

12:17
09/20/17
09/20
12:17
09/20/17
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBRY

BlackBerry

$9.14

-0.12 (-1.30%)

, DLPH

Delphi

$100.97

0.07 (0.07%)

12:16
09/20/17
09/20
12:16
09/20/17
12:16
Periodicals
Delphi picks BlackBerry's QNX OS for self-driving platform, CNet reports »

Delphi (DLPH) has…

BBRY

BlackBerry

$9.14

-0.12 (-1.30%)

DLPH

Delphi

$100.97

0.07 (0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

$NYE

NYSE Market Internals

12:16
09/20/17
09/20
12:16
09/20/17
12:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADP

ADP

$107.48

0.93 (0.87%)

12:15
09/20/17
09/20
12:15
09/20/17
12:15
Hot Stocks
Ackman says can work with ADP CEO after 'spoiled brat' comment »

Pershing Square's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:15
09/20/17
09/20
12:15
09/20/17
12:15
General news
FOMC balance sheet »

FOMC balance sheet: the…

ADP

ADP

$107.48

0.93 (0.87%)

12:14
09/20/17
09/20
12:14
09/20/17
12:14
Hot Stocks
Ackman says ADP margin opportunity closer to 1,200 basis points »

Pershing Square's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMG

Chipotle

$309.39

5.98 (1.97%)

12:12
09/20/17
09/20
12:12
09/20/17
12:12
Hot Stocks
Ackman says Chipotle management doing 'all the right things' »

Pershing Square's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADP

ADP

$107.48

0.93 (0.87%)

12:11
09/20/17
09/20
12:11
09/20/17
12:11
Hot Stocks
ADP does not want shares held by Pershing supporters, Ackman says »

Pershing Square's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$921.81

6.81 (0.74%)

, GOOGL

Alphabet Class A

$936.86

7.11 (0.76%)

12:11
09/20/17
09/20
12:11
09/20/17
12:11
Periodicals
Google nears deal to buy assets from HTC, Bloomberg reports »

Google is nearing a deal…

GOOG

Alphabet

$921.81

6.81 (0.74%)

GOOGL

Alphabet Class A

$936.86

7.11 (0.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 29

    Nov

HMNY

Helios and Matheson

$5.70

2.22 (63.79%)

12:10
09/20/17
09/20
12:10
09/20/17
12:10
Periodicals
Helios and Matheson mentioned cautiously by TheStreetSweeper 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADP

ADP

$107.48

0.93 (0.87%)

, PAYX

Paychex

$58.07

-0.01 (-0.02%)

12:09
09/20/17
09/20
12:09
09/20/17
12:09
Hot Stocks
Ackman says 80% of ADP's issue is margins not at Paychex level »

Pershing Square's…

ADP

ADP

$107.48

0.93 (0.87%)

PAYX

Paychex

$58.07

-0.01 (-0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

ADP

ADP

$107.48

0.93 (0.87%)

12:08
09/20/17
09/20
12:08
09/20/17
12:08
Hot Stocks
Ackman says ADP products are not easy enough to use »

Pershing Square's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADP

ADP

$107.48

0.93 (0.87%)

12:06
09/20/17
09/20
12:06
09/20/17
12:06
Hot Stocks
Ackman says ADP overstates total shareholder returns under CEO »

Pershing Square's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LUXTY

Luxottica

$57.52

0.06 (0.10%)

, ESLOY

Essilor

$63.35

-0.06 (-0.09%)

12:06
09/20/17
09/20
12:06
09/20/17
12:06
Downgrade
Luxottica, Essilor rating change  »

Luxottica downgraded to…

LUXTY

Luxottica

$57.52

0.06 (0.10%)

ESLOY

Essilor

$63.35

-0.06 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSEC

Prospect Capital

$6.72

0.07 (1.05%)

12:05
09/20/17
09/20
12:05
09/20/17
12:05
Options
Prospect Capital call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.